Press release
Hypersomnia Clinical Trials, Drugs, Companies, Hypersomnia Treatment Market, 2025 | Avadel, Centessa Pharmaceuticals (UK) Limited, Takeda
Hypersomnia Pipeline Insights 2025
Hypersomnia Overview:
Hypersomnia is a disorder marked by excessive daytime sleepiness, which can greatly disrupt daily activities, productivity, and overall quality of life. It often results in sudden, unplanned episodes of sleep or drowsiness, known as sleep attacks, without obvious signs of tiredness beforehand. As a significant public health issue, hypersomnia is linked to increased risks of motor vehicle accidents and workplace injuries. Among its forms, Idiopathic Hypersomnia (IH) stands out as a rare, chronic condition characterized by an uncontrollable urge to sleep, prolonged and non-refreshing naps, and difficulty waking up, even after sufficient or extended nighttime sleep. First described by Bedrich Roth in 1956, IH is believed to have a neurological basis, though its exact underlying mechanisms are still not well understood, posing challenges for both diagnosis and treatment.
Request for a detailed insights report on Hypersomnia pipeline insights @ https://www.delveinsight.com/report-store/hypersomnia-pipeline-insight [https://www.delveinsight.com/report-store/hypersomnia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Hypersomnia Pipeline Insight 2025 [https://www.delveinsight.com/sample-request/hypersomnia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Hypersomnia Therapeutics Market.
Key Takeaways from the Hypersomnia Pipeline Report
*
DelveInsight's Hypersomnia pipeline report depicts a robust space with 3+ active players working to develop 4+ pipeline therapies for Hypersomnia treatment.
*
YOLT-203 received Rare Pediatric Disease Designation in September 2024. This in vivo gene-editing therapy has initiated patient dosing, with a Phase 1 study expected to conclude by January 2026.
*
The FDA granted Rare Pediatric Disease Designation to META-001-PH in August 2024. Preclinical studies indicated up to an 80% reduction in urinary oxalate excretion. A Phase 1 trial is planned for early 2025.
*
In December 2024, the FDA approved a Phase 1/2 clinical trial for ABO-101, a gene-editing therapy targeting the HAO1 gene. This liver-directed treatment aims to provide a one-time solution by reducing oxalate production. The redePHine trial is expected to commence in the first half of 2025.
*
In October 2023, the FDA approved Rivfloza for patients aged 9 and older with PH1 and relatively preserved kidney function. This once-monthly subcutaneous RNAi therapy inhibits lactate dehydrogenase, a key enzyme in oxalate production. The approval was based on the PHYOX2 trial, which showed significant reductions in 24-hour urinary oxalate excretion.
*
Key Hypersomnia companies such as Avadel, Centessa Pharmaceuticals (UK) Limited, Takeda, and others are evaluating new drugs for Hypersomnia to improve the treatment landscape.
Hypersomnia Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Hypersomnia Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypersomnia treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Hypersomnia market.
Download our free sample page report on Hypersomnia pipeline insights @https://www.delveinsight.com/report-store/hypersomnia-pipeline-insight [https://www.delveinsight.com/report-store/hypersomnia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Hypersomnia Emerging Drugs
*
FT218: Avadel
FT218 (LUMRYZ) is an extended-release formulation of sodium oxybate developed to treat cataplexy and excessive daytime sleepiness (EDS) in adults with narcolepsy. It functions as a central nervous system depressant, targeting gamma-aminobutyric acid (GABA) receptors to help regulate the sleep-wake cycle and alleviate narcolepsy symptoms. Unlike conventional twice-nightly oxybate therapies, LUMRYZ offers the convenience of a single, bedtime-only dose, improving patient compliance. The drug is currently in Phase III development for the treatment of hypersomnia.
*
ORX750: Centessa Pharmaceuticals (UK) Limited
ORX750 is an experimental, orally administered drug that acts as a highly potent and selective agonist of the orexin receptor 2 (OX2R), specifically developed to address the underlying cause of orexin neuron loss in narcolepsy type 1 (NT1). In laboratory studies, ORX750 demonstrated strong activation of OX2R with an in vitro EC50 of 0.11 nM and showed 9,800 times greater selectivity for OX2R over the human orexin receptor 1 (hOX1R). ORX750 is Centessa's first orexin-targeting candidate, currently under development for treating narcolepsy, with potential applications for narcolepsy type 2 (NT2), idiopathic hypersomnia (IH), and other sleep-wake disorders. The drug is currently in Phase II clinical trials for hypersomnia treatment.
Hypersomnia Companies
There are around three or more major companies working on developing therapies for Hypersomnia. Among them, Avadel has a drug candidate currently in the most advanced stage, specifically Phase III of clinical development.
DelveInsight's report covers around 4+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Hypersomnia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Hypersomnia Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Hypersomnia Therapies and Key Companies: Hypersomnia Clinical Trials and advancements [https://www.delveinsight.com/sample-request/hypersomnia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Hypersomnia Pipeline Therapeutic Assessment
- Hypersomnia Assessment by Product Type
- Hypersomnia By Stage
- Hypersomnia Assessment by Route of Administration
- Hypersomnia Assessment by Molecule Type
Download Hypersomnia Sample report to know in detail about the Hypersomnia treatment market @ Hypersomnia Therapeutic Assessment [https://www.delveinsight.com/report-store/hypersomnia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Hypersomnia Current Treatment Patterns
4. Hypersomnia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Hypersomnia Late-Stage Products (Phase-III)
7. Hypersomnia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Hypersomnia Discontinued Products
13. Hypersomnia Product Profiles
14. Hypersomnia Key Companies
15. Hypersomnia Key Products
16. Dormant and Discontinued Products
17. Hypersomnia Unmet Needs
18. Hypersomnia Future Perspectives
19. Hypersomnia Analyst Review
20. Appendix
21. Report Methodology
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hypersomnia-clinical-trials-drugs-companies-hypersomnia-treatment-market-2025-avadel-centessa-pharmaceuticals-uk-limited-takeda]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hypersomnia Clinical Trials, Drugs, Companies, Hypersomnia Treatment Market, 2025 | Avadel, Centessa Pharmaceuticals (UK) Limited, Takeda here
News-ID: 3993070 • Views: …
More Releases from ABNewswire
Improving Social Skills and Communication: Flywheel Centers Details the Benefits …
Flywheel Centers explains how ABA therapy improves social skills and communication in children with autism in Charlotte, NC, offering personalized support for growth.
Charlotte, NC - Autism Spectrum Disorder (ASD) is a developmental condition that affects how individuals communicate, interact, and process information. For families in Charlotte, NC, seeking effective therapies to support their loved ones with autism, Applied Behavior Analysis (ABA) therapy has proven to be a valuable tool. ABA…
Stellar Scientific Explains Why Gravity Convection Ovens Are Perfect for Delicat …
Stellar Scientific explains how gravity convection ovens ensure consistent and delicate heating, making them perfect for precision cooking in various industries.
In laboratory and industrial environments, precision and consistency are crucial when it comes to heating applications. Whether it's for drying, sterilizing, or sample preparation, a stable and uniform heat distribution ensures accurate results. Gravity convection ovens, known for their reliability and delicate temperature control, are an ideal solution for such…
Unlocking Potential with ABA Therapy: How A Gem of Joy ABA Helps Children with A …
A Gem of Joy ABA in Baltimore, MD, uses ABA therapy to unlock potential in children with autism, helping them develop key skills for a brighter future.
Baltimore, MD - Autism Spectrum Disorder (ASD) affects millions of children worldwide, presenting unique challenges in communication, behavior, and social interaction. For families in Baltimore, MD, finding effective therapies is essential in helping children with autism reach their full potential. A Gem of Joy…
The Healing Power of Art: How Creative Therapy Zone in Thornhill, ON, Uses Art T …
Creative Therapy Zone in Thornhill, ON, harnesses the healing power of art therapy, helping individuals improve mental wellness through creative expression and support.
Thornhill, ON - Mental wellness is an essential aspect of overall health, and individuals facing mental health challenges often seek therapeutic approaches that go beyond traditional talk therapy. Art therapy has emerged as a powerful tool for individuals looking to express themselves, process emotions, and heal through creativity.…
More Releases for Hypersomnia
Europe Hypersomnia Market Size, Share, Growth Trends, and Forecast 2025 to 2032
"
The global Hypersomnia market is experiencing significant growth, driven by a confluence of factors including an increasing awareness of sleep disorders, advancements in diagnostic tools, and the development of novel treatment options. Hypersomnia, characterized by excessive daytime sleepiness or prolonged nighttime sleep, significantly impacts an individual's quality of life, affecting work performance, cognitive function, and overall well-being. The growing recognition of these impacts has led to a rise in diagnoses…
Hypersomnia Drug Market Set to Surge with Novel Therapies and Heightened Awarene …
The global hypersomnia drug market is entering a pivotal growth phase, driven by rising diagnosis rates, breakthroughs in sleep medicine, and expanding healthcare infrastructure. Hypersomnia-a spectrum of disorders characterized by excessive daytime sleepiness, prolonged nighttime sleep, and impaired alertness-impacts millions worldwide, undermining quality of life, workplace productivity, and safety. As research sheds light on the complex neurobiology of sleep regulation, pharmaceutical developers are racing to deliver targeted therapies that correct…
Empowering Growth: Hypersomnia Therapeutics Market 2025 and Industry Segments Ex …
A new Report by CoherentMI, titled "Hypersomnia Therapeutics Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2032," offers a comprehensive analysis of the industry, which comprises insights on the Hypersomnia Therapeutics market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market.
The Global Hypersomnia Therapeutics Market is estimated to be valued at USD 321.3 Mn in 2024 and is expected to reach USD 500.3…
Idiopathic Hypersomnia Treatment Market Analysis by Trends, Technological Advanc …
This Idiopathic Hypersomnia Treatment market analysis report aims to provide a solid platform to reduce business risks and deal with major changes take place in the business. Successful company strategies provided here help major players to expand business and make an effective business growing plan. It helps key organizations to deal with continuously changing business scenario. It eases different company activities around the company. This Idiopathic Hypersomnia Treatment market study…
Global Hypersomnia Drug Market: What are the top drivers and challenges? With To …
LOS ANGELES, United States: The research study presented in this report offers complete and intelligent analysis of the competition, segmentation, dynamics, and geographical advancement of the global Hypersomnia Drug market. It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Hypersomnia Drug market. The authors of the report have segmented the global Hypersomnia Drug market as per…
Hypersomnia Therapeutics- Pipeline Analysis 2018
Hypersomnia is a medical condition which is characterized by excessive daytime sleepiness. It is categorized into primary hypersomnia and secondary hypersomnia. People with hypersomnia also suffer from other sleep-related problems, such as clear thinking problems and lack of energy.
Download the sample report @ https://www.pharmaproff.com/request-sample/1101
Some of the most common causes of hypersomnia are sleep apnea, obesity, alcohol abuse, smoking, cardiovascular disorders, kidney diseases, neurological disorders, and depression.
Get the detailed analysis @…
